PharmAthene Inc

Find Ratings Reports
PIP : AMEX : Health Care
$0.7268 | %
Today's Range: 0.71 - 0.7399
Avg. Daily Volume: 4470000.0
04/28/17 - 4:02 PM ET

Financial Analysis

PHARMATHENE INC's gross profit margin for the fourth quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. Even though sales decreased, the net income has increased. PHARMATHENE INC has average liquidity. Currently, the Quick Ratio is 1.08 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 16.87% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q4 FY16 Q4 FY15
Net Sales ($mil)1.121.27
EBITDA ($mil)-5.48-0.88
EBIT ($mil)-5.51-0.91
Net Income ($mil)77.8-1.24

Balance Sheet Q4 FY16 Q4 FY15
Cash & Equiv. ($mil)220.8115.57
Total Assets ($mil)224.7419.86
Total Debt ($mil)0.00.0
Equity ($mil)19.4616.65

Profitability Q4 FY16 Q4 FY15
Gross Profit Margin-489.72-69.38
EBITDA Margin-489.72-69.37
Operating Margin-492.67-71.98
Sales Turnover0.020.54
Return on Assets86.25-17.32
Return on Equity996.21-20.66
Debt Q4 FY16 Q4 FY15
Current Ratio1.097.91
Interest Expense0.00.01
Interest Coverage0.0-130.29

Share Data Q4 FY16 Q4 FY15
Shares outstanding (mil)67.7364.38
Div / share0.00.0
Book value / share0.290.26
Institutional Own % n/a n/a
Avg Daily Volume4463760.0965785.0


HOLD. PHARMATHENE INC's P/E ratio indicates a significant discount compared to an average of 37.21 for the Biotechnology industry and a significant discount compared to the S&P 500 average of 24.92. To use another comparison, its price-to-book ratio of 2.71 indicates valuation on par with the S&P 500 average of 2.99 and a significant discount versus the industry average of 11.43. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. Upon assessment of these and other key valuation criteria, PHARMATHENE INC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
PIP 0.27 Peers 37.21   PIP 0.26 Peers 24.72

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

PIP is trading at a significant discount to its peers.


Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

PIP is trading at a significant discount to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
PIP NA Peers 43.15   PIP NA Peers 0.49

Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.

Ratio not available.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
PIP 2.71 Peers 11.43   PIP 4983.33 Peers 149.25

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

PIP is trading at a significant discount to its peers.


Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

PIP is expected to have an earnings growth rate that significantly exceeds its peers.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
PIP 10.10 Peers 191.95   PIP -50.86 Peers 395.13

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

PIP is trading at a significant discount to its industry on this measurement.


Lower. A sales growth rate that trails the industry implies that a company is losing market share.

PIP significantly trails its peers on the basis of sales growth



Latest Stock Upgrades/Downgrades